Oxford Biomedica plc (OTCMKTS:OXBDF – Free Report) – Research analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Oxford Biomedica in a report issued on Tuesday, April 30th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings of ($0.22) per share for the year, down from their prior forecast of ($0.19). The consensus estimate for Oxford Biomedica’s current full-year earnings is ($0.40) per share.
Oxford Biomedica Price Performance
OXBDF opened at $3.79 on Friday. Oxford Biomedica has a fifty-two week low of $2.09 and a fifty-two week high of $6.02. The business has a 50-day moving average of $2.57 and a 200-day moving average of $2.53.
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Featured Articles
- Five stocks we like better than Oxford Biomedica
- The “How” and “Why” of Investing in 5G Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- Industrial Products Stocks Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- ESG Stocks, What Investors Should Know
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
